Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
124M
-
Number of holders
-
384
-
Total 13F shares, excl. options
-
121M
-
Shares change
-
-59.5K
-
Total reported value, excl. options
-
$4.64B
-
Value change
-
+$384K
-
Put/Call ratio
-
0.45
-
Number of buys
-
175
-
Number of sells
-
-170
-
Price
-
$38.20
Significant Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q3 2023
435 filings reported holding HALO - HALOZYME THERAPEUTICS, INC. - Common Stock as of Q3 2023.
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) has 384 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 121M shares
of 124M outstanding shares and own 98.22% of the company stock.
Largest 10 shareholders include BlackRock Inc. (18.1M shares), VANGUARD GROUP INC (13.1M shares), Artisan Partners Limited Partnership (7.71M shares), STATE STREET CORP (6.21M shares), SNYDER CAPITAL MANAGEMENT L P (4.32M shares), MACQUARIE GROUP LTD (3.44M shares), ALLIANCEBERNSTEIN L.P. (3.36M shares), JPMORGAN CHASE & CO (3.16M shares), GEODE CAPITAL MANAGEMENT, LLC (2.79M shares), and MARSHALL WACE, LLP (2.72M shares).
This table shows the top 384 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.